Pedro M. Folegatti - Concepedia

Author

Pedro M. Folegatti

Also Known As

Adam Finn, Flaxman, AL, Folegatti, Pedro Moreira, P.M. Folegatti, Pedro Folegatti, Pedro M Folegatti, Pedro M. Folegatti, Pedro Moreira Folegatti

Publications

15.1K

Citations

H-Index

Concepts

All Affiliations

University of Oxford Jenner Institute Centre for Human Genetics University of Southampton Public Health England

About

Pedro M. Folegatti is an author at University of Oxford specializing in vaccine development, vaccination, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	4.3K
2	Immunology	9	9	4.3K
3	Autoimmunity	2	2	646
4	Allergy	1	1	633
5	Pathology	1	1	38

Pedro M. Folegatti

Publications

12.5K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2020	5K
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley, The Lancet VaccinationVaccine SafetyPhase 1/2Vaccine DevelopmentPreliminary Report	2020	2.6K
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2021	1.2K
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley, The Lancet	2021	649
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial Katie Ewer, Jordan R. Barrett, Sandra Belij‐Rammerstorfer, Nature Medicine VaccinationVaccine DevelopmentAllergyImmunologyImmunodominance	2020	633
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley, reponame:Expeditio Repositorio Institucional UJTL VaccinationVaccine SafetyPhase 1/2Vaccine DevelopmentPreliminary Report	2020	536
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses Jordan R. Barrett, Sandra Belij‐Rammerstorfer, Christina Dold, Nature Medicine VaccinationPhase 1/2Vaccine DevelopmentImmunologyHumoral Immunity	2020	334
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial John Frater, Katie Ewer, Ane Ogbe, The Lancet HIV	2021	253
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) Amy Flaxman, Natalie G. Marchevsky, Daniel Jenkin, The Lancet	2021	253
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial Pedro M. Folegatti, Mustapha Bittaye, Amy Flaxman, The Lancet Infectious Diseases	2020	236

Page 1